Appl. No.

: 10/773,628

Filed

February 5, 2004

AMENDMENTS TO THE CLAIMS

- 1. 45. (Cancelled)
- 46. (Currently Amended) An isolated glycoconjugate peptide comprising an HIV gp120 a binding fragment of a CD4 receptor for HIV gp120 synthetically conjugated to gal α (1,3) gal β .
- 47. (Previously Presented) The isolated glycoconjugate peptide of Claim 46, wherein said glycoconjugate peptide is linear.
- 48. (Currently Amended) The isolated glycoconjugate peptide of Claim 46, wherein said gal α (1,3) gal β is synthetically conjugated to said HIV gp120 binding fragment of a CD4 receptor for HIV-gp120 by attachment at one amino acid.
- 49. (Currently Amended) The isolated glycoconjugate peptide of Claim 46, wherein said <u>HIV gp120</u> binding fragment of a CD4 receptor for HIV gp120 is less than 200 amino acids in length.
- 50. (Currently Amended) The isolated glycoconjugate peptide of Claim 46, wherein said <u>HIV gp120</u> binding fragment of a CD4 receptor for HIV gp120 is less than 150 amino acids in length.
- 51. (Currently Amended) The isolated glycoconjugate peptide of Claim 46, wherein said <u>HIV gp120</u> binding fragment of a CD4 receptor for HIV gp120 is less than 100 amino acids in length.
- 52. (Currently Amended) The isolated glycoconjugate peptide of Claim 46, wherein said <u>HIV gp120</u> binding fragment of a CD4 receptor for HIV gp120 is less than 50 amino acids in length.
- 53. (Currently Amended) The isolated glycoconjugate peptide of Claim 46, wherein said <u>HIV gp120</u> binding fragment of a CD4 receptor-for HIV gp120 is less than 25 amino acids in length.
- 54. (Currently Amended) The isolated glycoconjugate peptide of Claim 46, wherein said <u>HIV gp120</u> binding fragment of a CD4 receptor for <u>HIV gp120</u> is less than or equal to 15 amino acids in length.

Appl. No. : 10/773,628 Filed : February 5, 2004

55. (Previously Presented) The isolated glycoconjugate peptide of Claim 46, wherein said gal α (1,3) gal β is synthetically conjugated to a hydroxylated amino acid.

- 56. (Previously Presented) The isolated glycoconjugate peptide of Claim 46, wherein said gal α (1,3) gal β is synthetically conjugated by an NH₂-linkage.
- 57. (Currently Amended) The isolated glycoconjugate peptide of Claim 46, wherein said gal α (1,3) gal β is synthetically conjugated to the N-terminal end of said <u>HIV gp120</u> binding fragment of a CD4 receptor for HIV gp120.
- 58. (Previously Presented) The isolated glycoconjugate peptide of Claim 48, wherein said gal α (1,3) gal β is synthetically conjugated to a hydroxylated amino acid.
- 59. (Previously Presented) The isolated glycoconjugate peptide of Claim 48, wherein said gal α (1,3) gal β is synthetically conjugated by an NH₂-linkage.
- 60. (Currently Amended) The isolated glycoconjugate peptide of Claim 48, wherein said gal α (1,3) gal β is synthetically conjugated to the N-terminal end of HIV gp120 binding fragment of a CD4 receptor for HIV gp120.
 - 61. 70, (Cancelled)